Yvonne Sherrer, MD

Yvonne Sherrer, MD
 

Medical Director/Director of Clinical Research
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, FL

What triggers do you use in your RA patients to begin a DMARD or biologic agent? Video

What triggers do you use in your RA patients to begin a DMARD or biologic agent?

What triggers do you use in your RA patients to begin a DMARD or biologic agent?
Yvonne Sherrer, MD

Yvonne Sherrer, MD

Under what circumstances do you use monotherapy with methotrexate and when do you use combination therapy and intensify treatment with a biologic agent? Video

Under what circumstances do you use monotherapy with methotrexate and when do you use combination therapy and intensify treatment with a biologic agent?

Under what circumstances do you use monotherapy with methotrexate and when do you use combination therapy and intensify treatment with a biologic agent?
Yvonne Sherrer, MD

Yvonne Sherrer, MD

What side effects are you most concerned about when using TNFIs or IL-6 inhibitors? Video

What side effects are you most concerned about when using TNFIs or IL-6 inhibitors?

What side effects are you most concerned about when using TNFIs or IL-6 inhibitors?
Yvonne Sherrer, MD

Yvonne Sherrer, MD

Have advantages been documented for IL-6 inhibitors that are fully human such as sarilumab? Video

Have advantages been documented for IL-6 inhibitors that are fully human such as sarilumab?

Have advantages been documented for IL-6 inhibitors that are fully human such as sarilumab?
Yvonne Sherrer, MD

Yvonne Sherrer, MD

How good are the disease outcome metrics recommended by ACR and what are their limitations? Video

How good are the disease outcome metrics recommended by ACR and what are their limitations?

How good are the disease outcome metrics recommended by ACR and what are their limitations?
Yvonne Sherrer, MD

Yvonne Sherrer, MD

When a suboptimal clinical response is encountered with TNF or interleukins antagonists, what other strategies may be effective? How might an IL-6 inhibitor fit into the treatment plan? Video

When a suboptimal clinical response is encountered with TNF or interleukins antagonists, what other strategies may be effective? How might an IL-6 inhibitor fit into the treatment plan?

When a suboptimal clinical response has been encountered with TNF or interleukins antagonists, what other biologic strategies have been shown to be effective in clinical trials? How are these sequencing decisions made and where might an ...
Yvonne Sherrer, MD

Yvonne Sherrer, MD

Is there a "one-sequence-fits-all" strategy? Or can one start with any of the biologic agents as an initial therapy in conjunction with methotrexate? Video

Is there a "one-sequence-fits-all" strategy? Or can one start with any of the biologic agents as an initial therapy in conjunction with methotrexate?

Is there a “one-sequence-fits-all” strategy? Or can one start with any of the biologic agents as an initial therapy in conjunction with methotrexate?
Yvonne Sherrer, MD

Yvonne Sherrer, MD

And how do you approach the biologically naive patient? Video

And how do you approach the biologically naive patient?

And how do you approach the biologically naïve patient?
Yvonne Sherrer, MD

Yvonne Sherrer, MD

What do studies and guidelines suggest as successful therapeutic strategies for RA patients who have been inadequate responders to TNF therapy? Video

What do studies and guidelines suggest as successful therapeutic strategies for RA patients who have been inadequate responders to TNF therapy?

What do studies and guidelines suggest as successful therapeutic strategies for RA patients who have been inadequate responders to TNF therapy? On the basis of what criteria is the decision made to switch to an Il-6 inhibitor or an agent ...
Yvonne Sherrer, MD

Yvonne Sherrer, MD

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS)? Video

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS)?

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS) that are being used in clinical trials?
Yvonne Sherrer, MD

Yvonne Sherrer, MD

What do you think are some of the most important unmet needs in RA? Video

What do you think are some of the most important unmet needs in RA?

What do you think are some of the most important unmet needs in RA?
Yvonne Sherrer, MD

Yvonne Sherrer, MD